The recent announcement by Brisbane based Progen that they would discontinue their PI-88 drug development comes as a wake up call for the entire Biotech industry.
The Board of Progen announced that the reasons underlying this about face in strategy were based on issues around patient recruitment, regulatory issues and clinical site initiation amongst others. We [...]

[Read more →]